ImmunoGen, Inc. (IMGN - Free Report) was a big mover last session, as the company saw its shares rise over 17% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 27.6% in the past one-month time frame.
The stock gained after the company made a decision to partner with Jazz Pharmaceuticals PLC (JAZZ - Free Report) to develop and commercialize two early-stage, hematology-related antibody-drug conjugate (ADC) programs.
The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for ImmunoGen. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
ImmunoGen, Inc. Price
ImmunoGen currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
A better-ranked stock in the Medical sector is Jazz Pharmaceuticals PLC (JAZZ - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is IMGN going up? Or down? Predict to see what others think: Up or Down
4 Surprising Tech Stocks to Keep an Eye On
Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really take off.
See Stocks Now>>